Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print October 11, 2006, doi:10.1212/01.wnl.0000243231.12248.67)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 67, Number 10, November 28, 2006
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000243231.12248.67v1
67/10/1860    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Neurology
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Babovic-Vuksanovic, D.
Right arrow Articles by O’Neill, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Babovic-Vuksanovic, D.
Right arrow Articles by O’Neill, B.
Related Collections
Right arrow All Oncology
Right arrow Nerve tumor
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow Neurofibromatosis
NEUROLOGY 2006;67:1860-1862
© 2006 American Academy of Neurology
Brief Communications

Phase II trial of pirfenidone in adults with neurofibromatosis type 1

D. Babovic-Vuksanovic, MD, K. Ballman, PhD, V. Michels, MD, P. McGrann, MD, N. Lindor, MD, B. King, MD, J. Camp, V. Micic, N. Babovic, X. Carrero, R. Spinner, MD and B. O’Neill, MD

From Department of Medical Genetics (D.B.-V., V.M., P.M., N.L.), Radiology (B.K.), Neurology (B.O.), and Neurosurgery (R.S.); Biomedical Imaging Resource (J.C., V.M. N.B.); and Health Sciences Research (X.C.), Mayo College of Medicine, Rochester, MN

Address correspondence and reprint requests to Dr. Dusica Babovic-Vuksanovic, Department of Medical Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; e-mail: dbabovic{at}mayo.edu

We performed an open-label phase II trial of oral pirfenidone in 24 patients with neurofibromatosis type 1 (NF1). Tumors were monitored by three-dimensional MRI. At the end of treatment, four patients had a decrease in tumor volume by 15% or more, three had tumor progression, and 17 remained stable. Pirfenidone warrants further investigation in NF1, which has until now lacked an effective control therapy.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the November 28 issue to find the title link for this article.

This article was previously published in electronic format as an Expedited E-Pub on October 11, 2006, at www.neurology.org.

Supported by Clinical Investigator Award, Mayo Foundation (D.B.-V). Neurofibromatosis Inc., Minnesota Chapter, provided financial support for volumetric analysis of MRIs (grant NFIM#1 to D.B.-V.).

Disclosure: Pirfenidone was provided by Solanan, Inc. The authors report no other conflicts of interest.

These data were presented as a poster at the Congress of European Society for Human Genetics, Prague, May 12 to 16, 2005.

Received December 1, 2005. Accepted in final form August 1, 2006.


Related articles in Neurology:

November 28 Highlights

Neurology 2006 67: 1736-1737. [Full Text]  



This article has been cited by other articles:


Home page
 CJASNHome page
F. S. Shihab
Do We Have a Pill for Renal Fibrosis?
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 876 - 878.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.